Literature DB >> 20056147

Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production.

Marjan Gharagozloo1, Enrico Velardi, Stefano Bruscoli, Massimiliano Agostini, Moises Di Sante, Valerio Donato, Zahra Amirghofran, Carlo Riccardi.   

Abstract

Silymarin, a mixture of bioactive flavonolignans isolated from Silybum marianum, exhibits anti-carcinogenic, anti-inflammatory and cytoprotective effects. In this study, the in vitro immunomodulatory activity of silymarin was investigated using CD4+ splenocytes from C57/Bl6 mice. Proliferation assay revealed that silymarin, at 50 microM concentration, significantly inhibited CD4+ cells proliferation. ELISA analyses indicated that silymarin significantly inhibited IL-2 and IFN-gamma production. Immunofluorescence staining performed on the mouse hybridoma T cell line (3DO) revealed a block of nuclear translocation of transcription factor kappaB (NF-kappaB), which is known to be responsible for IL-2 transcriptional activation. Moreover, silymarin inhibited p65/NF-kappaB phosphorylation in CD4+ T cell. These results suggest that silymarin is able to inhibit T cell activation and proliferation, notably acting on pathways of NF-kappaB activation/translocation. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20056147     DOI: 10.1016/j.phrs.2009.12.017

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  16 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

Review 2.  Dietary agents in cancer prevention: an immunological perspective.

Authors:  Ya Ying Zheng; Bharathi Viswanathan; Pravin Kesarwani; Shikhar Mehrotra
Journal:  Photochem Photobiol       Date:  2012-03-30       Impact factor: 3.421

3.  The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice.

Authors:  M Galuppo; G Nocentini; E Mazzon; S Ronchetti; E Esposito; L Riccardi; P Sportoletti; R Di Paola; S Bruscoli; C Riccardi; S Cuzzocrea
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

4.  Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis.

Authors:  Hílton Antonio Mata-Santos; Fabiana Gonçalves Lino; Carolina Carneiro Rocha; Claudia Neto Paiva; Morgana Teixeira Lima Castelo Branco; Alexandre dos Santos Pyrrho
Journal:  Parasitol Res       Date:  2010-08-07       Impact factor: 2.289

Review 5.  Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.

Authors:  Partha Palit; Aparna Mukhopadhyay; Debprasad Chattopadhyay
Journal:  Phytother Res       Date:  2021-04-04       Impact factor: 6.388

Review 6.  Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives.

Authors:  Peter F Surai
Journal:  Antioxidants (Basel)       Date:  2015-03-20

Review 7.  Recent advances in the herbal treatment of non-alcoholic Fatty liver disease.

Authors:  Jia Xiao; Kwok Fai So; Emily C Liong; George L Tipoe
Journal:  J Tradit Complement Med       Date:  2013-04

8.  "Silymarin", a promising pharmacological agent for treatment of diseases.

Authors:  Gholamreza Karimi; Maryam Vahabzadeh; Parisa Lari; Marziyeh Rashedinia; Mohammad Moshiri
Journal:  Iran J Basic Med Sci       Date:  2011-07       Impact factor: 2.699

Review 9.  Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015.

Authors:  Hadi Darvishi Khezri; Ebrahim Salehifar; Mehrnoush Kosaryan; Aily Aliasgharian; Hossein Jalali; Arash Hadian Amree
Journal:  Adv Pharmacol Sci       Date:  2016-02-21

10.  Silymarin for the Prevention of Contrast-Induced Nephropathy: A Placebo-Controlled Clinical Trial.

Authors:  Zohreh Sedighifard; Farshad Roghani; Peyman Bidram; Samaneh Aalami Harandi; Safieh Molavi
Journal:  Int J Prev Med       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.